A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Phase 2TerminatedNCT02810951

Castle Creek Biosciences, LLC.6 enrolled

Overview

The purpose of this study is to evaluate the safety of FCX-007, evaluate Type VII collagen (COL7) expression and the presence of anchoring fibrils and to analyze wound healing as a result of FCX-007 administration in subjects with recessive dystrophic epidermolysis bullosa (RDEB). Funding Source- FDA OOPD

RDEB is a rare skin and connective tissue disease characterized clinically by skin fragility with easy blistering, erosion and scarring of skin and mucous membranes, and caused by the deficiency of the protein type VII collagen (COL7). The objective of this study is evaluate the safety of FCX-007 intradermal injections in RDEB subjects. Additionally, the trial will evaluate COL7 expression, the presence of anchoring fibrils, as well evidence of wound healing. Approximately twelve subjects are expected to enroll in the Phase I/II trial. Phase I will enroll approximately six adult subjects. Phase II will enroll approximately six subjects both adults and pediatric (aged seven (7) years or older). All subjects will receive FCX-007 to one or more paired target RDEB wounds. Proof of mechanism will be monitored through digital photography of target wounds and assays conducted on biopsies taken from intact skin sites where FCX-007 is administered.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Epidermolysis Bullosa Dystrophica, Recessive

Interventions

FCX-007GENETIC

FCX-007 is a genetically modified cell product obtained from the subject's own skin cells (Autologous fibroblasts). The cells are expanded and genetically modified to produce functional COL7. FCX-007 cell suspension is injected intradermally.

Eligibility

Sex: ALLMin age: 7 Years

Medical Language ↔ Plain English

Key Inclusion Criteria: 1. Age 1. Phase I: Eighteen (18) years or older. 2. Phase II: Seven (7) years or older. 2. Diagnosis of recessive dystrophic epidermolysis bullosa (RDEB) Key Exclusion Criteria: 1. Medical instability limiting ability to travel to the investigative center. 2. Active infection with HIV, hepatitis B or hepatitis C or evidence of other systemic infection 3. Current evidence of metastatic squamous cell carcinoma at the site to be injected 4. Clinically significant abnormal laboratory result or other significant clinical abnormalities 5. Receipt of a chemical or biological study product for the specific treatment of RDEB in the past six months

Locations (2)

Stanford University

Stanford, California, United States

Children's Hospital Colorado

Aurora, Colorado, United States

Outcomes

Primary Outcomes

Adverse Events

Number of subjects with adverse events.

Time frame: 52 weeks post treatment

Secondary Outcomes

Complete Wound Closure

Percentage of target wounds achieving complete wound closure (greater than 90%) at all post-baseline visits

Time frame: Through Week 52

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.